Vir Biotechnology's hepatitis delta therapy meets primary endpoint in Phase 3 trial
VIR•Vir Biotechnology said its elebsiran-tobevibart combination met the primary endpoint in the Phase 3 ECLIPSE 1 trial for chronic hepatitis delta. Monthly treatment achieved undetectable virus with normalized liver enzymes; additional pivotal trial results are expected in the first quarter of 2027, ahead of a planned FDA submission in mid-2027.
1. Trial results
Vir Biotechnology's elebsiran-tobevibart combination met the primary endpoint in the pivotal Phase 3 ECLIPSE 1 trial for chronic hepatitis delta. Monthly treatment achieved undetectable virus with normalized liver enzymes and was well tolerated, with no treatment interruptions or discontinuations.
2. Next steps
The results were presented at the American Association for the Study of Liver Diseases' The Liver Meeting 2026 in Denver. Additional pivotal trial results are expected in the first quarter of 2027, supporting a planned FDA submission in mid-2027.
